NX-13: Clinical Trials

1 trial of NX-13, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow NX-13: new trials by email Literature Review of NX-13 trials Research Report on NX-13

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis
Phase 2TerminatedAbbVie812023-04-242026-06-15

Conditions studied

Colitis, Ulcerative (1)  ·  Lymphoma, Follicular (1)

Sponsors

AbbVie (1)

Countries

Belgium (1)  ·  Italy (1)  ·  Poland (1)  ·  United States (1)